Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.59 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CNR1 | P21554 | 3/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246948 | 0.86 | PRSS12 (0.65) | PRSS12NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL14246766 | 0.82 | TAS1R3 (0.60) | PRSS12TAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL15931655 | 0.80 | NPC1 (0.62) | PRSS12NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL3457719 | 0.77 | RAB9A (0.87) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL701934 | 0.74 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL3390949 | 0.74 | CNR1 (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1CNR1 | |
| SCHEMBL6515255 | 0.74 | CNR1 (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1CNR1 | |
| SCHEMBL5436807 | 0.73 | HTT (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL2406255 | 0.73 | HTT (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL24334864 | 0.73 | HTT (0.68) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | PRSS12 1225/4885NPC1 493/4885RAB9A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.